Dr. Qaiser Bashir, MD

Dr. Bashir practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bashir's NPI, 1972640241, was assigned on January 30, 2007. Dr. Bashir graduated from King Edward Medical University in 2001. Dr. Bashir holds Texas license N2397.

Dr. Bashir's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bashir's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bashir practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bashir's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bashir is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Bashir's licenses on file in 11 states: Texas, Florida, Tennessee, Washington, Alabama, Arizona, Georgia, Louisiana, Mississippi, Oklahoma and Colorado.

Dmand AI lists anemia, coronary artery disease, enlarged thyroid, fibromyalgia and chronic pain, high cholesterol, low blood pressure, pneumonia and respiratory infection and purpura and thrombocytopenia among the conditions Dr. Bashir treats.

CMS data shows 386 Medicare services from Dr. Bashir across 3 procedure codes in 2024, for 103 Medicare patients. Medicare paid $29,104 for them.

CMS counts 103 Medicare patients who saw Dr. Bashir in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 3.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bashir's median patient age at 69, with 41% women.

In 2024, Dr. Bashir wrote 156 Medicare Part D claims for 28 patients. 81% of them were for generic drugs. CMS names the drug for 42 of them, across 3 drugs with 11 or more claims each, at $354,829 in total drug cost. In 2023, CMS named 41 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bashir for performance year 2024, reported as part of a group. Dr. Bashir accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bashir as offering telehealth.

Dmand AI links 149 papers to Dr. Bashir, published from 2010 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Hematopoietic Stem Cell Transplantation, Multiple Myeloma and Transplantation, Autologous. Dr. Bashir has published most often in Biol Blood Marrow Transplant. Dr. Bashir's most frequent co-authors are Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD and Uday R. Popat, MD.

Dmand AI links Dr. Bashir to 2 clinical trials. Conditions studied include Multiple Myeloma and Blood Protein Disorders. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 26 general payments to Dr. Bashir from 10 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 74% of the total. Purdue Pharma L.P. paid the most, $5,568.

Dr. Bashir graduated from King Edward Medical University in 2001.

Dr. Bashir is in network with 5 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.